Prolactinoma - which patients react favorably to cabergoline medication?
Objective. Prolactinoma, as a common endocrine disorder and the most frequent type of pituitary tumor, acts primarily as a suppressor on the gonadal functions. It is generally successfully treated with dopamine agonists; however, treatment resistance still remains in an unneglectable ratio. In this...
Main Authors: | Karatas Savas, Hacioglu Yalcin, Rakicioglu Taskin |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2022-10-01
|
Series: | Endocrine Regulations |
Subjects: | |
Online Access: | https://doi.org/10.2478/enr-2022-0030 |
Similar Items
-
Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
by: Bassam M Flamerz Arkawazi
Published: (2020-01-01) -
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
by: Shruti Khare, et al.
Published: (2017-01-01) -
Spontaneous reduction of prolactinoma post cabergoline withdrawal
by: Sampath Kumar Venkatesh, et al.
Published: (2012-01-01) -
Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma
by: Mazhar Muslum Tuna, et al.
Published: (2015-03-01) -
The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
by: Larisa Dzeranova, et al.
Published: (2016-11-01)